Skip to main content
Quest Diagnostics Home

Alzheimer's and Dementia Testing

The Coming Alzheimer's Disease Healthcare Revolution: US Physician and Adult Perspectives on the Future of Diagnostics and Treatment

A  new report from Quest Diagnostics, reveals physician and US adult perspectives on the current and future landscape of dementia and Alzheimer's disease (AD) evaluation, testing, treatment and care. Findings highlight the important role diagnostics may play in the next era of AD.

Download the report now

474

NOW AVAILABLE

Assessing Alzheimer's risk starts with a single blood test

Introducing QUEST AD-DetectTM Amyloid Beta 42/40 ratio. Analytically validated and less invasive,2 this testing solution can help evaluate patients, inform potential treatment decisions and monitor patients over time.
Learn more
eBook

Stay up to date on our latest findings, reports, and test offerings around Alzheimer's disease.

Subscribe

Join our email community

Get the very latest news and information from Quest Advanced® Neurology.

Sign up

About our tests

Latest research and resources

Leading the conversation around Alzheimer's research and the latest testing innovations

Hear from Dr Stephen Salloway and Dr Michael Racke as they discuss the current opportunities and challenges in diagnosing Alzheimer's Disease, the emerging role of blood-based biomarkers in AD screening and monitoring, and new diagnostic pathways.
Watch the Webinar
design images

Enhancing diagnostic specificity with the help of Phospho-Tau biomarkers

Alzheimer's can be difficult to diagnose. ADmark® Phospho-Tau/Total Tau/Aβ42 Analysis and Interpretation, includes a set of 3 biomarkers that differentiates Alzheimer's disease (AD) from other forms of dementia.3
ADmark® Phospho-Tau/Total Tau/Aβ42 Analysis Interpretation PDF
design images

Offering one of the most comprehensive neurological testing portfolios in the industry

Explore our testing solutions and see how we can work together to bring patients to the end of their diagnostic journey.
Find a Test
design images

1. Quest Advanced Neurology. The Coming Alzheimer's Disease Healthcare Revolution: U.S. Physician and Adult Perspectives on the Future of Diagnostics and Treatment (2022)

2. Data on file. Quest Diagnostics; 2022.

3. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease. Arch Gen Psychiatry. 2004;61(1):95-102. doi:10.1001/ archpsyc.61.1.95 Image content features a model and is intended for illustrative purposes only

Test codes may vary by location. Please contact your local laboratory for more information.

Our company

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.